Can Fite Biopharma Ltd Company Profile (NYSEMKT:CANF)

About Can Fite Biopharma Ltd (NYSEMKT:CANF)

Can Fite Biopharma Ltd logoCan Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company's drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:CANF
  • CUSIP: N/A
  • Web: www.canfite.co.il
Average Prices:
  • 50 Day Moving Avg: $1.81
  • 200 Day Moving Avg: $1.91
P/E:
  • Trailing P/E Ratio: 7.1896
  • P/E Growth: 0.0000
Profitability:
  • Net Margins: -2,453.03%
  • Return on Equity: -57.94%
  • Return on Assets: -32.52%
Debt:
  • Current Ratio: 7.29%
Misc:
  • Beta: 1.2
 
Frequently Asked Questions for Can Fite Biopharma Ltd (NYSEMKT:CANF)

What is Can Fite Biopharma Ltd's stock symbol?

Can Fite Biopharma Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CANF."

How were Can Fite Biopharma Ltd's earnings last quarter?

Can Fite Biopharma Ltd (NYSEMKT:CANF) announced its quarterly earnings results on Tuesday, May, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. Can Fite Biopharma Ltd had a negative net margin of 2,453.03% and a negative return on equity of 57.94%. View Can Fite Biopharma Ltd's Earnings History.

Where is Can Fite Biopharma Ltd's stock going? Where will Can Fite Biopharma Ltd's stock price be in 2017?

2 brokerages have issued 12-month price targets for Can Fite Biopharma Ltd's shares. Their predictions range from $6.00 to $6.00. On average, they expect Can Fite Biopharma Ltd's share price to reach $6.00 in the next year. View Analyst Ratings for Can Fite Biopharma Ltd.

Who are some of Can Fite Biopharma Ltd's key competitors?

How do I buy Can Fite Biopharma Ltd stock?

Shares of Can Fite Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Can Fite Biopharma Ltd (NYSEMKT CANF)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Can Fite Biopharma Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Can Fite Biopharma Ltd (NYSEMKT:CANF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00

Analysts' Ratings History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Show:
DateFirmActionRatingPrice TargetDetails
10/18/2016Roth CapitalReiterated RatingBuyView Rating Details
8/29/2016Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
4/4/2016HC WainwrightReiterated RatingBuy$6.00View Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Earnings by Quarter for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Earnings History by Quarter for Can Fite Biopharma Ltd (NYSEMKT CANF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/31/2016Q116($0.09)($0.12)ViewN/AView Earnings Details
5/29/2015Q115($0.12)($0.04)ViewN/AView Earnings Details
4/8/2015($0.15)($0.20)ViewN/AView Earnings Details
12/2/2014($0.24)($0.10)ViewN/AView Earnings Details
9/3/2014($0.36)($0.20)ViewN/AView Earnings Details
5/30/2014($0.23)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Current Year EPS Consensus Estimate: $-0.31 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS

Dividends

Dividend History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Latest Headlines for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Source:
DateHeadline
seekingalpha.com logoCan-Fite on go with mid-stage study of namodenoson in fatty liver disease
seekingalpha.com - July 19 at 11:07 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient ... - StreetInsider.com
www.streetinsider.com - July 17 at 5:19 PM
finance.yahoo.com logoCan-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
finance.yahoo.com - July 17 at 5:19 PM
finance.yahoo.com logoCan-Fite to Participate in Bio International Convention in San Diego on June 19-22, 2017
finance.yahoo.com - June 15 at 4:29 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Concludes Successful Investigator Meeting for ACRobat Phase III Trial of Piclidenoson in ... - StreetInsider.com
www.streetinsider.com - June 10 at 9:14 PM
finance.yahoo.com logoCan-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis
finance.yahoo.com - June 8 at 10:25 AM
prnewswire.com logoCan-Fite Establishes Clinical Advisory Board for NAFLD/NASH - PR Newswire (press release)
www.prnewswire.com - June 5 at 9:04 PM
finance.yahoo.com logoCan-Fite Establishes Clinical Advisory Board for NAFLD/NASH
finance.yahoo.com - June 5 at 12:25 PM
prnewswire.com logoCan-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update - PR Newswire (press release)
www.prnewswire.com - June 1 at 4:37 PM
streetinsider.com logoForm 6-K Can-Fite BioPharma Ltd. For: Jun 01 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - June 1 at 4:37 PM
finance.yahoo.com logoNew Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017
finance.yahoo.com - June 1 at 4:37 PM
reuters.com logoBRIEF-Can Fite Biopharma files for resale of up to 2.8 mln ordinary shares by selling shareholders - SEC filing
www.reuters.com - May 30 at 9:13 PM
streetinsider.com logoForm 6-K Can-Fite BioPharma Ltd. For: May 30 - StreetInsider.com
www.streetinsider.com - May 30 at 4:12 PM
seekingalpha.com logoCan-Fite Biopharma reports Q1 results
seekingalpha.com - May 30 at 12:14 PM
finance.yahoo.com logoCan-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update
finance.yahoo.com - May 30 at 12:13 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Files CTA in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis ... - StreetInsider.com
www.streetinsider.com - May 18 at 11:25 AM
reuters.com logoBRIEF-Can-Fite files clinical trial application in Canada for Piclidenoson
www.reuters.com - May 16 at 11:17 AM
seekingalpha.com logoCan-Fite files clinical trial application in Canada ahead of Phase 3 Piclidenoson study
seekingalpha.com - May 16 at 11:17 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Files CTA in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
www.streetinsider.com - May 16 at 11:17 AM
finance.yahoo.com logoCan-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
finance.yahoo.com - May 16 at 11:17 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
www.streetinsider.com - May 4 at 4:15 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH - StreetInsider.com
www.streetinsider.com - May 3 at 8:20 AM
finance.yahoo.com logoCan-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
finance.yahoo.com - May 3 at 8:20 AM
seekingalpha.com logoCan-Fite advancing late-stage study of piclidenoson in RA; shares ahead 9%
seekingalpha.com - April 26 at 3:00 PM
benzinga.com logo25 Stocks Moving In Wednesday's Pre-Market Session - Benzinga
www.benzinga.com - April 26 at 3:00 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Phase III ACRobat Trial in RA Approved by Institutional Review Board - StreetInsider.com
www.streetinsider.com - April 26 at 3:00 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Phase III ACRobat Trial in RA Approved by Institutional Review Board
www.streetinsider.com - April 25 at 4:00 PM
finance.yahoo.com logoCan-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board
finance.yahoo.com - April 25 at 12:22 PM
prnewswire.com logoCan-Fite Reports 2016 Financial Results & Provides Clinical Update - PR Newswire (press release)
www.prnewswire.com - March 31 at 9:18 PM
reuters.com logoBRIEF-Can-Fite sees FY 2019 sales $1.4 billion
www.reuters.com - March 31 at 4:16 PM
finance.yahoo.com logoCan-Fite Reports 2016 Financial Results & Provides Clinical Update
finance.yahoo.com - March 31 at 4:16 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says New Preclinical Data Shows Namodenoson Prevents Progression of Liver Fibrosis - StreetInsider.com
www.streetinsider.com - March 2 at 9:23 PM
msn.com logoCan Fite Biopharma (CANF) Jumps on Clinical Data
www.msn.com - February 28 at 4:22 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says New Preclinical Data Shows Namodenoson Prevents Progression of Liver Fibrosis
www.streetinsider.com - February 28 at 4:21 PM
msn.com logo25 Stocks Moving In Tuesday's Pre-Market Session
www.msn.com - February 28 at 9:29 AM
us.rd.yahoo.com logoNew Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis
us.rd.yahoo.com - February 28 at 9:29 AM
us.rd.yahoo.com logo7:16 am Can-Fite BioPharma announces new data that 'show its liver disease drug candidate Namodenoson (CF102) prevented liver (hepatic) fibrosis progression in preclinical studies'
us.rd.yahoo.com - February 28 at 9:29 AM
finance.yahoo.com logoCANF: Ready to Start Two Phase III Trials in 2017
finance.yahoo.com - February 23 at 4:07 PM
streetinsider.com logoForm 6-K Can-Fite BioPharma Ltd. For: Feb 08
www.streetinsider.com - February 8 at 4:24 PM
streetinsider.com logoForm 6-K Can-Fite BioPharma Ltd. For: Feb 08 - StreetInsider.com
www.streetinsider.com - February 8 at 4:24 PM
finance.yahoo.com logoCan-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
finance.yahoo.com - February 8 at 4:24 PM
finance.yahoo.com logo7:31 am Can-Fite BioPharma announces $5 mln registered direct offering at $2.00/share
finance.yahoo.com - January 20 at 10:25 PM
benzinga.com logo15 Biggest Mid-Day Losers For Thursday - Benzinga
www.benzinga.com - January 20 at 3:21 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Reports $5M Registered Direct Offering - StreetInsider.com
www.streetinsider.com - January 20 at 3:21 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Reports $5M Registered Direct Offering
www.streetinsider.com - January 19 at 10:20 PM

Social

This page was last updated on 7/23/2017 by MarketBeat.com Staff